Small molecule · Inhibitor of B-cell lymphoma 2 (BCL2) · developed by Ascentage Pharma Group
Lisaftoclax is an orally bioavailable selective inhibitor of Bcl-2, an anti-apoptotic protein overexpressed in many cancers. By inhibiting Bcl-2, it restores apoptotic processes in tumor cells. It is studied in chronic lymphocytic leukemia, acute myeloid leukemia, multiple myeloma, and other hematologic malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06641414 | Phase 3 | Higher-risk Myelodysplastic Syndrome | Recruiting | AAPG |
| NCT06389292 | Phase 3 | Acute Myeloid Leukemia | Recruiting | AAPG |
| NCT06104566 | Phase 3 | CLL/SLL | Recruiting | AAPG |
| NCT05147467 | Phase 2 | Chronic Lymphocytic Leukemia | Recruiting | AAPG |
| NCT04942067 | Phase 1/2 | Multiple Myeloma | Unknown | AAPG |
| NCT04964518 | Phase 1/2 | AML, Adult | Unknown | AAPG |
| NCT04494503 | Phase 1/2 | Chronic Lymphocytic Leukemia | Recruiting | AAPG |
| NCT06401603 | Phase 1 | Advanced Chronic Myeloid Leukemia | Recruiting | AAPG |
| NCT05517616 | Phase 1 | Pharmacokinetics | Completed | AAPG |
| NCT04260217 | Phase 1 | Waldenstrom Macroglobulinemia | Completed | AAPG |
| NCT04215809 | Phase 1 | CLL/SLL | Recruiting | AAPG |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Myeloid LeukemiaAdvanced Chronic Myeloid LeukemiaChronic Lymphocytic LeukemiaCLL/SLLHigher-risk Myelodysplastic SyndromePhiladelphia Chromosome-Positive Acute Myeloid LeukemiaSmall Lymphocytic LymphomaAML, AdultAmyloidosisMultiple MyelomaPharmacokineticsWaldenstrom Macroglobulinemia
Updated Oct 3, 2026. Something wrong or missing? Report it on the AAPG page.
See AAPG's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AAPG catalysts and pipeline →